Boston, MA and Boulder, CO – April 11, 2023 – ClinOne, the leading provider of Adaptive Experiences in clinical trials announced today it closed a $3 million Series A funding to accelerate the growth of its platform and broaden its reach to serve customers. This latest round, led by Boulder Ventures, with participation from existing investors CU Healthcare Innovation Fund and First Trust Capital Partners, will continue to advance ClinOne’s mission to offer flexible engagement solutions for all participants to support their clinical trial journey.
As part of this investment, Robert Conway will join the ClinOne Board as Executive Chair. Bob served as the Chief Executive Officer of Array BioPharma, Inc 1999 – 2012. He serves as the Chairman of ARCA, Biopharma and is on the board of directors of Signant Health and Alpine Immune Sciences. He is also a member of Genstar Capital’s Strategic Advisory Board. Bob previously served as Director of eResearch Technology (Clario), PRA International (acquired by ICON, plc), and Advarra Inc.
“We are thrilled to partner with Boulder Ventures to expand ClinOne’s reach in offering high-quality, rapidly deployed solutions for clinical trials,” said Andrea Valente, CEO at ClinOne. “Bob and I worked together at eRT, and it will be rewarding to work with him again and leverage his experience. We are proud of the work we are doing in partnership with our clients to make clinical trial participation easier for patients. Earning their collective trust is what we strive to achieve.”
ClinOne sells an integrated platform that offers comprehensive support for sites, participants, and caregivers throughout the clinical trial journey. From its Trial Awareness module for Healthcare Provider engagement to Patient Ride, Consent Management, Communities, and Medication Adherence, its cloud-based, no-code, multi-tenant platform provides an environment for rapid, efficient deployment and use.
Bob Conway shared, “The most significant opportunity to improve the clinical trial process is the ‘last mile’ serving sites and patients. ClinOne has built a platform which offers ease of use along with comprehensiveness and efficiency for all stakeholders to meet. Andrea has assembled a team with deep experience to realize these goals.”
“As longtime investors in the development of new drugs, ClinOne was a natural fit for Boulder Ventures,” said Kyle Lefkoff, General Partner and Founder of Boulder Ventures. “Participating in a pharmaceutical clinical trial is an act of conspicuous bravery by Patients. ClinOne makes their participation in clinical trials simple, reliable, and useful, and by offering flexibility, can reach a diverse group of participants. ClinOne plays an important role in making clinical trials experiences better for patients.”
About ClinOne
ClinOne connects, informs, and empowers patients, caregivers, and sites in clinical trials with a true single platform for trial awareness, consent management, and patient engagement – underpinned with comprehensive data insights tools and interoperability. Used by more than 80 sponsors, CROs, and site networks in 60 countries, our solutions are proven to reduce risk and simplify complex processes for therapeutic areas and patient populations including Oncology, Rare Disease, Pediatrics, the Elderly, and CNS. Designed in collaboration with sites and with participants and caregivers in mind, ClinOne features the industry’s fastest deployment, cost-efficient scale for trials of all sizes, and seamless API integrations to provide the results you need – and the experience your patients deserve. Ready to keep patients, sites, and study teams active and engaged throughout your clinical trial? Let’s get creative at http://www.clinone.com
About Boulder Ventures
Boulder Ventures invests in high potential Information Technology and Biotechnology companies. Founded in 1995, Boulder Ventures backs experienced entrepreneurs based in Colorado and the Mid-Atlantic region. http://www.boulderventures.com